Select Pharmaceuticals Portfolio
Select Pharmaceuticals Portfolio reported 47 holdings worth US$1.5B as of May 31, 2026 (Form N-PORT)
As of May 31, 2026 · Filed Jul 24, 2026
Select Pharmaceuticals Portfolio reported 47 holdings worth US$1.5B as of May 31, 2026. Largest: Eli Lilly And Company, Gsk Plc and Viatris Inc. Filed Jul 24, 2026 (Form N-PORT).
- Holdings
- 47
- Value as reported
- US$1.5B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 391K | US$432M | 28.8% |
| Gsk Plc | 4.82M | US$123M | 8.2% |
| Viatris Inc. | 5.03M | US$81.8M | 5.5% |
| Ucb S.a. | 260K | US$76.4M | 5.1% |
| Merck & Company, Inc. | 599K | US$71.2M | 4.7% |
| Roche Holding Ltd | 162K | US$68.2M | 4.5% |
| Astrazeneca Plc | 341K | US$63.4M | 4.2% |
| Elanco Animal Health Incorporated | 2.61M | US$62.3M | 4.1% |
| Jazz Pharmaceuticals Plc | 260K | US$61.4M | 4.1% |
| Gilead Sciences, Inc. | 443K | US$59.5M | 4.0% |
| Johnson & Johnson | 251K | US$56.6M | 3.8% |
| Royalty Pharma Plc | 719K | US$40.1M | 2.7% |
| Moderna, Inc. | 499K | US$23.6M | 1.6% |
| Intellia Therapeutics, Inc. | 1.27M | US$17.8M | 1.2% |
| Beam Therapeutics Inc. | 501K | US$16.5M | 1.1% |
| Axsome Therapeutics, Inc. | 69,000 | US$16.2M | 1.1% |
| Xenon Pharmaceuticals Inc. | 226K | US$12.4M | 0.82% |
| Ocular Therapeutix, Inc. | 1.33M | US$12M | 0.80% |
| Idexx Laboratories, Inc. | 16,200 | US$9.13M | 0.61% |
| Swedish Orphan Biovitrum Ab | 170K | US$8.15M | 0.54% |
| Ptc Therapeutics, Inc. | 110K | US$8.12M | 0.54% |
| Capricor Therapeutics, Inc. | 231K | US$6.93M | 0.46% |
| Kymera Therapeutics, Inc. | 84,500 | US$6.88M | 0.46% |
| Raia Drogasil S.a. | 1.69M | US$6.27M | 0.42% |
| Annexon, Inc. | 1M | US$5.44M | 0.36% |
| Arrowhead Pharmaceuticals, Inc. | 65,400 | US$5.1M | 0.34% |
| Harmony Biosciences Holdings, Inc. | 159K | US$5.01M | 0.33% |
| Crinetics Pharmaceuticals, Inc. | 131K | US$4.67M | 0.31% |
| Definium Therapeutics, Inc. | 188K | US$4.55M | 0.30% |
| Corcept Therapeutics Incorporated | 62,300 | US$4.33M | 0.29% |
| Uniqure N.v. | 147K | US$4.2M | 0.28% |
| Ascendis Pharma A/s | 18,300 | US$4.1M | 0.27% |
| Disc Medicine, Inc. | 53,800 | US$3.74M | 0.25% |
| Amylyx Pharmaceuticals, Inc. | 258K | US$3.7M | 0.25% |
| Phibro Animal Health Corporation | 99,800 | US$3.07M | 0.20% |
| Ionis Pharmaceuticals, Inc. | 40,100 | US$3.07M | 0.20% |
| Edgewise Therapeutics, Inc. | 83,600 | US$2.86M | 0.19% |
| Kailera Therapeutics, Inc. | 9,000 | US$206K | 0.01% |
| Merck Kgaa | 0 | US$0 | 0.00% |
| Viking Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Financiere De Tubize S.a. | 0 | US$0 | 0.00% |
| Idorsia Ltd. | 0 | US$0 | 0.00% |
| Wave Life Sciences Ltd. | 0 | US$0 | 0.00% |
| Summit Therapeutics Inc. | 0 | US$0 | 0.00% |
| Arrivent Biopharma, Inc. | 0 | US$0 | 0.00% |
| Vera Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Biogen Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related